XULTOPHY (insulin degludec/liraglutide) Patient Assistance Program
Don’t let the high cost of brand fixed-ratio basal insulin/GLP-1 RA combination therapy disrupt your diabetes management. We help eligible patients access Xultophy (insulin degludec/liraglutide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Xultophy 100/3.6 (insulin degludec 100 units/mL + liraglutide 3.6 mg/mL) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide. It is a once-daily fixed-ratio combination of ultra-long-acting basal insulin degludec and the GLP-1 receptor agonist liraglutide.
- Without assistance, brand Xultophy costs commonly run approximately $850–$1,050 per 5-pen pack (one month).
- Through AffordMyPrescriptions, qualifying patients can access Xultophy for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no biosimilar of Xultophy in the U.S. as of 2026. The other fixed-ratio basal insulin/GLP-1 RA combination is Soliqua (insulin glargine + lixisenatide). Components can be used separately: insulin degludec (Tresiba, brand only — no biosimilar yet), and liraglutide (Victoza brand, plus authorized generic liraglutide now available at lower cost). More potent GLP-1 RAs (Ozempic, Mounjaro) may be preferred. Medicare Part D $35/month insulin cap applies.
What Is Xultophy Prescription Assistance Program?
The Xultophy Prescription Assistance Program is a manufacturer-sponsored initiative that provides Xultophy at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for type 2 diabetes patients requiring intensified therapy who are uninsured or underinsured.
Navigating the program on your own means dealing with eligibility verification, endocrinology/primary care coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
Pharmacy Price Comparison
- Without assistance, Xultophy costs roughly $850–$1,050 per 5-pen pack. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$1,000 | Save ~$930/mo |
| CVS Pharmacy | ~$1,050 | Save ~$980/mo |
| Walmart | ~$890 | Save ~$820/mo |
| Costco | ~$870 | Save ~$800/mo |
Medicare Part D cap | $35/mo | Federal cap |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Xultophy Prescription Program?
The Patient Assistance Program is free to apply for and provides Xultophy at no medication cost if approved. Our $69.95/month service covers full advocacy. With authorized generic liraglutide and Medicare’s $35/month insulin cap, we’ll help your provider determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Xultophy:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $850–$1,050 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Xultophy assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Xultophy Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured Or Underinsured And Cannot Afford Your Medication
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Xultophy:
Xultophy 100/3.6 is a once-daily fixed-ratio combination of insulin degludec (ultra-long-acting basal insulin) and liraglutide (GLP-1 receptor agonist) in a single prefilled pen. The combination provides 24+ hour basal insulin coverage and the metabolic benefits of GLP-1 RA in one daily injection.
How Xultophy Works:
Xultophy is a once-daily combination injection of ultra-long-acting insulin degludec and the GLP-1 receptor agonist liraglutide, designed for Type 2 diabetes inadequately controlled on basal insulin alone. It improves glucose control, promotes satiety, and slows gastric emptying with less weight gain and hypoglycemia than escalating standard insulin. The fixed-ratio combination titrates both components proportionally based on the insulin dose. It provides stable, 24+ hour insulin coverage and can be administered at any time of day.
Form and use:
Xultophy is administered as a single, daily subcutaneous injection using a prefilled pen. It can be taken at any time of day, with or without meals, though maintaining a consistent daily timing is recommended. The daily dosage range spans from 10 to 50 units, and users should regularly rotate their injection sites. Dose titration is managed based on the patient’s fasting glucose levels, mirroring the process of titrating standard basal insulin.
Generic availability:
As of 2026, there is no biosimilar version of Xultophy available in the United States, with Soliqua serving as the alternative fixed-ratio combination on the market. Looking at the individual components, insulin degludec does not have a biosimilar yet, whereas liraglutide is available as a lower-cost authorized generic. While these components can be used separately, more potent GLP-1 receptor agonists like Ozempic or Mounjaro are often preferred alongside separate basal insulin for stronger glycemic and weight benefits.
Warnings:
Xultophy carries a boxed warning and contraindication for individuals with a personal or family history of medullary thyroid cancer or MEN2 due to thyroid C-cell tumor risks. Common insulin-related risks include hypoglycemia, hypokalemia, and fluid retention or heart failure when combined with TZDs. The GLP-1 component introduces potential risks of pancreatitis, acute gallbladder disease, acute kidney injury, and severe gastrointestinal side effects like nausea and vomiting. Additional warnings include diabetic retinopathy complications, severe hypersensitivity reactions, and rare reports of suicidal ideation.
FAQ (Frequently Asked Questions)
How Much Does Xultophy Cost Without Insurance?
Brand Xultophy costs approximately $850–$1,050 per 5-pen pack (one month). Medicare Part D beneficiaries pay $35/month maximum for covered insulin (which includes Xultophy). Through AffordMyPrescriptions, qualifying patients receive Xultophy at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Xultophy Different From Soliqua?
Both are fixed-ratio basal insulin/GLP-1 RA combinations. Xultophy = insulin degludec (ultra-long-acting) + liraglutide (longer-acting GLP-1 RA, dosing time flexible). Soliqua = insulin glargine + lixisenatide (short-acting GLP-1 RA, dosed before first meal). Xultophy may have slightly stronger glycemic effects (liraglutide > lixisenatide). Choice often depends on insurance coverage and dosing preferences.
Should I Consider Ozempic Or Mounjaro Instead?
Possibly. Ozempic (semaglutide) and Mounjaro (tirzepatide) are more potent than liraglutide — typically producing greater A1c reduction and more weight loss. For type 2 diabetes patients with significant cardiovascular disease, kidney disease, obesity, or substantial weight to lose, the more potent GLP-1 RAs are often preferred — used alongside separate basal insulin if needed. Discuss with your provider.
Why Insulin Degludec Vs. Glargine?
Insulin degludec has an ultra-long, flat 24+ hour action profile with a half-life of about 25 hours — providing very stable basal insulin coverage. Insulin glargine has a 24-hour profile with a slight peak. Degludec may have less day-to-day variability and potentially less nocturnal hypoglycemia than glargine. The trade-off: glargine has biosimilars (Semglee, Rezvoglar) at much lower cost; degludec does not yet have a biosimilar.
Can I Take Xultophy At Any Time Of Day?
Yes — Xultophy can be dosed at any time of day, with or without meals. The ultra-long-acting insulin degludec component provides flexibility. However, consistent timing is recommended for predictability — try to inject at approximately the same time each day. If you forget a dose, take it as soon as remembered, then continue at your regular time the next day (don’t double dose).
What About The Medicare $35 Insulin Cap?
Effective January 1, 2023, Medicare Part D capped patient out-of-pocket cost at $35/month per covered insulin product, including insulin combination products like Xultophy. Most Medicare beneficiaries pay $35/month for Xultophy under Part D.
What If My Application Is Denied?
If denied, we explore alternatives — switching to insulin degludec (Tresiba) plus authorized generic liraglutide separately (more dose flexibility), switching to Soliqua, switching to biosimilar insulin glargine plus standalone Ozempic/Trulicity/Mounjaro, the manufacturer’s copay program for commercially insured patients, Medicare $35/month cap, or independent foundations such as the American Diabetes Association or PAN Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Xultophy, our team may be able to help you access assistance programs — or guide you to a more affordable basal insulin + GLP-1 RA approach. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.